Answers are grounded in this paper and cite their sources.
FDA review recommends label updates for bisphosphonates, highlighting long-term use safety in osteoporosis treatment.
In response to reports of rare but serious adverse events associated with bisphosphonates, the FDA reviewed long-term bisphosphonate efficacy. Two FDA committees recommended an update to bisphosphonate labeling but no regulatory restriction on duration of use.
No takes yet. Share an insight, caveat, or question.
Whitaker et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: